Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from DCTH

Delcath Systems Stock Jumps After Data Update From Eye Cancer Trials At ASCO Meeting

Delcath Systems Inc (NASDAQ:DCTH) announced further details regarding presentations relating to its proprietary percutaneous hepatic perfusion (PHP) system. The CHOPIN trial assessed ipilimumab plus nivolumab (IPI+NIVO) combined with Delcath's proprietary liver-targeted PHP treatment in metastatic uveal melanoma patients. The poster reports a Best Overall Response of 1 complete response, five partial responses, and…

Benzinga · Jun 7, 2022

Delcath's Chemosat Hepatic Delivery System Shows Overall Response Rate Of 60.5% In Eye Cancer That Spreads To Liver

Delcath's Chemosat Hepatic Delivery System Shows Overall Response Rate Of 60.5% In Eye Cancer That Spreads To Liver

Delcath Systems Inc's (NASDAQ: DCTH) single-institution retrospective study data on CHEMOSAT Hepatic Delivery System for liver dominant metastatic uveal melanoma (mUM)

Benzinga · Feb 4, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

1

Coverage From

Benzinga

Organisations

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play